United Capital Financial Advisors’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.24M Buy
6,786
+531
+8% +$97.8K 0.01% 682
2025
Q4
$1.1M Buy
6,255
+822
+15% +$134K 0.01% 705
2025
Q3
$761K Buy
5,433
+411
+8% +$55.6K 0.01% 731
2025
Q2
$631K Buy
5,022
+1,644
+49% +$205K 0.01% 726
2025
Q1
$462K Sell
3,378
-1,496
-31% -$214K ﹤0.01% 771
2024
Q4
$745K Sell
4,874
-82,501
-94% -$13.9M 0.01% 623
2024
Q3
$16.9M Sell
87,375
-1,803
-2% -$377K 0.14% 139
2024
Q2
$20.7M Sell
89,178
-2,198
-2% -$478K 0.18% 113
2024
Q1
$19.7M Sell
91,376
-3,894
-4% -$912K 0.16% 124
2023
Q4
$24.7M Sell
95,270
-70,369
-42% -$17.3M 0.2% 105
2023
Q3
$42.6M Sell
165,639
-21,170
-11% -$5.66M 0.28% 76
2023
Q2
$53.2M Sell
186,809
-2,767
-1% -$824K 0.29% 70
2023
Q1
$52.7M Sell
189,576
-2,362
-1% -$654K 0.29% 70
2022
Q4
$53.2M Sell
191,938
-9,592
-5% -$2.71M 0.3% 72
2022
Q3
$53.8M Sell
201,530
-1,231
-0.6% -$261K 0.32% 67
2022
Q2
$41.4M Buy
202,761
+2,942
+1% +$601K 0.23% 89
2022
Q1
$42.1M Buy
199,819
+39,640
+25% +$8.62M 0.2% 101
2021
Q4
$38.4M Buy
160,179
+3,538
+2% +$910K 0.18% 120
2021
Q3
$44.3M Buy
156,641
+3,248
+2% +$1.06M 0.22% 95
2021
Q2
$53.1M Buy
153,393
+1,197
+0.8% +$363K 0.27% 75
2021
Q1
$42.6M Buy
152,196
+21,407
+16% +$5.77M 0.24% 92
2020
Q4
$32M Buy
130,789
+3,583
+3% +$924K 0.19% 115
2020
Q3
$36.1M Buy
127,206
+9,617
+8% +$2.68M 0.24% 99
2020
Q2
$31.5M Buy
117,589
+13,943
+13% +$4.19M 0.23% 100
2020
Q1
$31.6M Sell
103,646
-3,519
-3% -$1.07M 0.26% 86
2019
Q4
$31.8M Buy
107,165
+7,654
+8% +$2.12M 0.21% 106
2019
Q3
$23.2M Buy
99,511
+4,523
+5% +$1.05M 0.16% 144
2019
Q2
$22.2M Buy
94,988
+26,360
+38% +$6.09M 0.15% 149
2019
Q1
$16.2M Buy
68,628
+5,146
+8% +$1.62M 0.11% 196
2018
Q4
$19.1M Buy
63,482
+5,680
+10% +$1.81M 0.15% 141
2018
Q3
$20.4M Buy
57,802
+2,045
+4% +$704K 0.14% 157
2018
Q2
$16.2M Buy
55,757
+2,576
+5% +$724K 0.12% 187
2018
Q1
$14.6M Buy
53,181
+2,847
+6% +$884K 0.11% 205
2017
Q4
$16.1M Buy
50,334
+2,590
+5% +$831K 0.13% 193
2017
Q3
$14.9M Buy
47,744
+2,743
+6% +$812K 0.13% 194
2017
Q2
$12.2M Buy
45,001
+6,257
+16% +$1.65M 0.11% 224
2017
Q1
$10.6M Buy
38,744
+6,156
+19% +$1.74M 0.1% 246
2016
Q4
$8.51M Sell
32,588
-10,369
-24% -$3.07M 0.08% 290
2016
Q3
$13.4M Buy
42,957
+4,395
+11% +$1.3M 0.13% 182
2016
Q2
$9.33M Sell
38,562
-1,183
-3% -$312K 0.1% 256
2016
Q1
$10.3M Buy
39,745
+2,448
+7% +$647K 0.11% 193
2015
Q4
$11.4M Buy
37,297
+1,184
+3% +$340K 0.13% 176
2015
Q3
$10.5M Buy
36,113
+14,732
+69% +$4.87M 0.13% 178
2015
Q2
$8.64M Buy
21,381
+25
+0.1% +$10K 0.1% 242
2015
Q1
$7.99M Sell
21,356
-6,719
-24% -$2.65M 0.1% 260
2014
Q4
$9.53M Buy
28,075
+20,200
+257% +$6.53M 0.14% 167
2014
Q3
$2.6M Buy
+7,875
New +$2.6M 0.05% 375
2014
Q2
Sell
-7,845
Closed -$2.4M 803
2014
Q1
$2.4M Buy
7,845
+665
+9% +$211K 0.05% 329
2013
Q4
$2.01M Sell
7,180
-1,263
-15% -$327K 0.07% 239
2013
Q3
$2.03M Sell
8,443
-1,339
-14% -$300K 0.06% 250
2013
Q2
$2.1M Buy
+9,782
New +$2.09M 0.06% 304

Other funds holding BIIB

United Capital Financial Advisors's BIIB Position: Q1 2026 in Review

United Capital Financial Advisors increased its Biogen (BIIB) stake by 8.5% in Q1 2026, buying an estimated $97.8K and bringing the position to 6,786 shares worth $1.24M. The position accounts for 0.01% of the portfolio, ranked #682.

United Capital Financial Advisors first reported a position in BIIB in Q2 2013 and has held it in 51 quarters since. The position peaked at $53.8M in Q3 2022. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • United Capital Financial Advisors held 6,786 shares of Biogen worth $1.24M as of Q1 2026.
  • United Capital Financial Advisors bought 531 Biogen shares in Q1 2026, an estimated $97.8K.
  • Biogen made up 0.01% of United Capital Financial Advisors's portfolio in Q1 2026, its #682 holding.
  • United Capital Financial Advisors first reported a position in Biogen in Q2 2013 and has held it in 51 quarters since.
  • United Capital Financial Advisors's Biogen position peaked at $53.8M in Q3 2022.
  • 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on United Capital Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.